Download our whitepaper,

Age-Related Macular Degeneration:
Clinical Trial Strategies and
Innovation

What's Inside:

  • Epidemiology and risk factors of Age-Related Macular Degeneration (AMD).
  • Clinical endpoints: visual acuity, OCT imaging, and progression measures.
  • Anti-VEGF therapy trials and emerging treatments.
  • Patient selection and biomarker-driven enrollment strategies.
  • Safety monitoring protocols for intravitreal injections.
  • Regulatory pathways for ophthalmology drug approvals.

Access your complimentary whitepaper today:






    Age-Related Macular Degeneration Clinical Trials

    Age-Related Macular Degeneration (AMD) is a leading cause of vision loss in older adults worldwide. Clinical trials in this area focus on evaluating novel therapies, particularly anti-VEGF agents, gene therapies, and combination treatments that aim to preserve or improve vision.

    Recent advancements in imaging technologies, such as Optical Coherence Tomography (OCT), have revolutionized the ability to monitor disease progression and treatment response in AMD trials. These tools provide critical data on retinal thickness, fluid accumulation, and anatomical changes.

    iNGENū CRO brings extensive experience in designing and executing AMD clinical trials. Our team works closely with ophthalmology centers equipped with state-of-the-art imaging facilities, ensuring high-quality data collection and standardized protocols across all sites.

    AMD affects approximately

    8.7%

    of the global population aged 45-85 years

    Anti-VEGF therapy has shown

    90%

    success in stabilizing or improving vision

    OCT imaging provides

    5-micron

    resolution for detailed retinal analysis

    Our clinical team has over

    120 years

    of combined clinical trial experience